CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 885 participants.

Also called NCT05681351

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 885 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05681351
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Slovakia, South Africa, Spain, Sweden, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05681351. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-13 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
Olezarsen
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05681351
Content hash
ab3340695f5706ef09aea2edf21e27513a0a29e3c1cc1fccf393141762dfe694